Q4 2024 Management View CEO Michel Brousset highlighted that 2024 was a transformative year for Waldencast, with strong performance from its brands, Milk Makeup and Obagi Medical, both significantly ...

TD Cowen lowered the firm’s price target on Waldencast (WALD) to $3.40 from $4.30 and keeps a Hold rating on the shares. The firm updated its ...

Waldencast ( NASDAQ:WALD ) Full Year 2024 Results Key Financial Results Revenue: US$273.9m (up 26% from FY 2023). Net... Waldencast PLC (WALD) reports robust revenue increases and secures a new ...

Net Revenue of $72.1 million, 29.4% Comparable Net Revenue Growth and $11.2 million of Adjusted EBITDA, doubling from Q4 2023FY 2024 Net ...

LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced its ...

Waldencast reports Q4 2024 net revenue of $72.1 million, 29.4% growth, and $11.2 million adjusted EBITDA, doubling year-over-year. Net Loss decreased only slightly from $32.7 million in Q4 2023 to ...

Waldencast (NASDAQ:WALD – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at DA Davidson in a ...

Telsey Advisory analyst Dana Telsey maintained a Buy rating on Waldencast Acquisition (WALD – Research Report) today and set a price target of ...

Telsey Advisory Group reiterated their outperform rating on shares of Waldencast (NASDAQ:WALD – Free Report) in a research note published on Wednesday morning,Benzinga reports. Telsey Advisory Group ...

Waldencast is set to report Q4 earnings, with analysts projecting $81.69M sales. The company expands Obagi globally while mitigating potential tariff impacts.

Michel Brousset, Waldencast Founder and CEO, said: “We closed a transformative year for the Group, achieving outstanding growth, expanding our brands' communities, and making significant ...